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A New Path (and Editor) for AJP
Kevin A. RothFrom the Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama (Editor-in-Chief)This year marks the 100th anniversary of the afﬁliation of
the American Society for Investigative Pathology (ASIP)
with the Federation of American Societies for Experimental
Biology. It is thus a special honor to be named the new
Editor-in-Chief of The American Journal of Pathology in
this centenary year. AJP, the ofﬁcial journal of this esteemed
society, has historically been one of the most prestigious
and frequently cited journals in the ﬁeld of pathology, and it
is my intent to enhance further the quality and recognition of
the Journal.
My editorial predecessors have served the Journal well,
and I thank past Editor-in-Chief Dr. Michael Lisanti and
Senior Associate Editor Dr. Herbert Tanowitz for their
assistance during the recent editorial transition. Dr. Lisanti’s
efforts to broaden the scope of AJP to include important
translational discoveries built on Dr. Jay McDonald’s
emphasis on the cellular and molecular mechanisms of
disease pathogenesis. Their leadership has positioned AJP
to advance both of these agendas. I would be remiss if I did
not acknowledge the contributions to AJP made by
Dr. Nelson Fausto. Dr. Fausto, who passed away last year
(see his In Memoriam published in the December issue of
AJP),1 was Editor-in-Chief from 1992 to 2000. In his ﬁnal
Editorial as Editor-in-Chief, Dr. Fausto wrote about the
future of pathology, and his words remain inspirational 13
years later: “We have much to contribute to medical
knowledge and are in a unique position to do it. But our
role will not come to us by default. Just the opposite is true:
we must actively pursue it, so that pathology is considered
as both the science of pathogenesis, on an equal footing
with other basic sciences, and a diagnostic discipline that is
complemented and strengthened by the new modalities of
genomic analyses.”2
AJP has been very successful in its goal of publishing
high-quality, original papers on the cellular and molecular
biology of disease as evidenced by a variety of citation
metrics. The 2011 Journal Citations Reports3 ranks AJP ﬁrst
out of 79 journals in Eigenfactor Score, ﬁfth in 5-Year
Impact Factor, and sixth in Article Inﬂuence Score. The
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http://dx.doi.org/10.1016/j.ajpath.2012.11.001AJP ﬁrst out of 172 journals in the subject category of
Pathology and Forensic Medicine in H-index (a measure
of the number of highly cited publications) (SCImago,
http://www.scimagojr.com/journalrank.php; last accessed
November 7, 2012). AJP was also recently ranked in the top
5% of all molecular and cell biology journals (29 out of
761) for cost effectiveness (http://www.eigenfactor.org/
costeffectiveness.php; last accessed November 7, 2012),
a fact that is well worth mentioning to your institutional
library director.
Despite these measures of success, AJP has been
struggling in perhaps the best-known and most-used
metric of all: the two-year Impact Factor. AJP’s Impact
Factor has been in steady decline for several years and is
now below ﬁve. For many reasons, a scientiﬁc journal’s
success should not be equated solely with its Impact
Factor.4 However, ignoring this measure of journal citation
frequency would be foolish. Underlying “drivers” of the
Impact Factor include the number of review articles, when
the review articles are published in the calendar year,
publication of special review or theme-based issues, and
manuscript acceptance rate, as well as the publication of
articles of wide scientiﬁc interest over narrowly focused
niche manuscripts that may receive fewer citations.
Ideally, AJP should meet ASIP’s publication goals while
maintaining an Impact Factor that attracts the highest
quality submissions. It is my objective as incoming Editor-
in-Chief to ensure this result.
To assist with this objective, I have assembled a team of
trusted colleagues to assist me. I am fortunate that Martha
B. Furie, Ph.D. (Stony Brook University, Stony Brook,
NY), a superb investigative pathologist with extensive
experience as a scientiﬁc editor and as a leader in ASIP,
has agreed to work with me as Senior Associate Editor. In
addition, Robin G. Lorenz, M.D., Ph.D., and John C.
Chatham, D.Phil., both from my home department
(Department of Pathology, University of Alabama at Bir-
mingham, Birmingham, AL) are joining AJP as Senior
Assistant Editors, bringing their respective expertise in
immunology and molecular and cellular pathology to bear.
EditorialIn combination with an excellent AJP Editorial Ofﬁce staff
and a dedicated ASIP Publications Committee, we are
committed to again making AJP the preeminent investi-
gative pathology journal. Some changes in journal opera-
tions will occur immediately, others will take time to
implement, and the effectiveness of these changes in
raising both AJP Impact Factor and visibility will take
years to measure. However, as Dr. Fausto so astutely
stated, “our role will not come to us by default.”2 I humbly
look forward to working with AJP contributors, ASIP
members, pathology investigators, and the broader scien-4tiﬁc community to enhance the scientiﬁc impact of AJP
over the next 5 years.References
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